2. Metabolic Enzyme/Protease
  3. Cytochrome P450
  4. Bergaptol

Bergaptol  (Synonyms: 5-Hydroxypsoralen; 4-Hydroxybergapten)

Cat. No.: HY-76316 Purity: 99.44%
SDS COA Handling Instructions

Molarity Calculator

Bergaptol is an inhibitor of debenzylation of the CYP3A4 enzyme with an IC50 of 24.92 μM. Recent studies have shown that it has anti-proliferative and anti-cancer properties.

For research use only. We do not sell to patients.

Bergaptol Chemical Structure

Bergaptol Chemical Structure

CAS No. : 486-60-2

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
5 mg USD 25 In-stock
10 mg USD 35 In-stock
25 mg USD 50 In-stock
50 mg USD 75 In-stock
100 mg USD 120 In-stock
500 mg USD 264 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Bergaptol:

Bergaptol Related Antibodies

Top Publications Citing Use of Products

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms
CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A4 CYP17A1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Bergaptol is an inhibitor of debenzylation of the CYP3A4 enzyme with an IC50 of 24.92 μM. Recent studies have shown that it has anti-proliferative and anti-cancer properties[1].

IC50 & Target

CYP3

 

Cellular Effect
Cell Line Type Value Description References
HT-29 IC50
> 500 μM
Compound: 9
Anticancer activity against human HT-29 cells after 72 hrs by MTT assay
Anticancer activity against human HT-29 cells after 72 hrs by MTT assay
[PMID: 19054677]
In Vitro

Bergaptol (0-800 ppm) shows free radical scavenging activity, tested by ABTS and DPPH methods[1].
Bergaptol (50 μg/mL, 24 h) inhibits LPS-induced production of NO, IL-6, and TNF-α in RAW264.7 cells[3].
Bergaptol (50 μg/mL, 24 h) inhibits LPS-induced MAPK phosphorylation and nuclear factor-kappa B (NF-κB) activation in RAW264.7 cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bergaptol Related Antibodies

Western Blot Analysis[3]

Cell Line: LPS-induced RAW264.7 cells
Concentration: 50 μg/mL
Incubation Time: 24 h
Result: Inhibited JNK phosphorylation and NF-κB activation.
Inhibited NF-κB P65 translocation from the cytosol to nucleus.
In Vivo

Bergaptol (10-40 mg/kg, i.p., once a day for two weeks) improves the cognitive impairment in LPS-treated mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: LPS (40 μg/kg, i.c.v.)-treated mice[4]
Dosage: 10-40 mg/kg
Administration: i.p., once a day for two week
Result: Reduced LPS-induced fixation and cleavage of neuronal nuclei in the CA1 region of the hippocampus (H&E staining).
Increasead the dendritic spine density of mice.
Inhibited LPS-induced neuroinflammation.
Molecular Weight

202.16

Formula

C11H6O4
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C=CC(C(O1)=C2)=C(O)C3=C2OC=C3
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : ≥ 50 mg/mL (247.33 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.9466 mL 24.7329 mL 49.4658 mL
5 mM 0.9893 mL 4.9466 mL 9.8932 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (12.37 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.44%

SDS (393 KB)

COA (251 KB) LCMS (268 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.9466 mL 24.7329 mL 49.4658 mL 123.6644 mL
5 mM 0.9893 mL 4.9466 mL 9.8932 mL 24.7329 mL
10 mM 0.4947 mL 2.4733 mL 4.9466 mL 12.3664 mL
15 mM 0.3298 mL 1.6489 mL 3.2977 mL 8.2443 mL
20 mM 0.2473 mL 1.2366 mL 2.4733 mL 6.1832 mL
25 mM 0.1979 mL 0.9893 mL 1.9786 mL 4.9466 mL
30 mM 0.1649 mL 0.8244 mL 1.6489 mL 4.1221 mL
40 mM 0.1237 mL 0.6183 mL 1.2366 mL 3.0916 mL
50 mM 0.0989 mL 0.4947 mL 0.9893 mL 2.4733 mL
60 mM 0.0824 mL 0.4122 mL 0.8244 mL 2.0611 mL
80 mM 0.0618 mL 0.3092 mL 0.6183 mL 1.5458 mL
100 mM 0.0495 mL 0.2473 mL 0.4947 mL 1.2366 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bergaptol Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bergaptol486-60-25-Hydroxypsoralen 4-HydroxybergaptenCytochrome P450CYPsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bergaptol
Cat. No.:
HY-76316
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.